medmix AG

medmix AG

MEDX · SW · Industrials / Specialty Industrial Machinery

10.38CHF+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close10.38
Open10.44
Day Range10.20 – 10.50
52-Week Range7.61 – 12.22
Volume27.11K
Market Cap412.47M
P/E (TTM)0.00
Forward P/E9.58
EPS0.00
Dividend Yield1.01%
Beta0.83
50-Day Avg9.05
200-Day Avg9.42

About

medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.

Company Details

  • SectorIndustrials
  • IndustrySpecialty Industrial Machinery
  • CEODr. Rene Willi Ph.D.
  • Employees2.59K
  • HeadquartersNeuhofstrasse 20, Baar, Switzerland, 6340, Switzerland
  • Websitehttps://www.medmix.swiss

Leadership

  • Dr. Rene Willi Ph.D.Chief Executive Officer · b. 1967
  • Mr. Sven LuginbuehlGroup Chief Financial Officer
  • Dr. Andreas Friis-HansenChief Operating Officer
  • Mr. Francisco FaoroChief Technology Officer
  • Mr. Domenico TruncellitoHead of Corporate Communications & Investor Relations
  • Mr. Schops XavierChief Legal Officer, Company Secretary & Head of Corporate Affairs · b. 1968
  • Mr. Jasper Den OudenChief Human Resources & Sustainability Officer · b. 1975
  • Ms. Jennifer DeanGlobal Head of Beauty Business Unit · b. 1968
  • Ms. Ayse SanliogluGlobal Head of Business Unit Dental
  • Mr. Roman ThoenigGlobal Head Business Segment Industry

Financials

Income Statement

Currency: CHF2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue454.00M420.70M351.30M457.30M477.10M486.60M483.90M448.00M
Growth (%)--7.33%-16.50%+30.17%+4.33%+1.99%-0.55%-7.42%
Cost of Revenue281.40M258.30M230.20M276.10M301.70M328.90M324.20M286.10M
Gross Profit172.60M162.40M121.10M181.20M175.40M157.70M159.70M161.90M
Gross Margin38.02%38.60%34.47%39.62%36.76%32.41%33.00%36.14%
Operating Expense109.70M124.20M103.00M121.30M155.80M141.70M146.80M134.50M
Operating Income62.90M38.20M18.10M59.90M19.60M16.00M12.90M27.40M
Operating Margin13.85%9.08%5.15%13.10%4.11%3.29%2.67%6.12%
EBITDA102.50M80.10M60.90M110.60M68.30M68.40M67.60M79.70M
EBITDA Margin22.58%19.04%17.34%24.19%14.32%14.06%13.97%17.79%
Net Income52.20M25.20M9.60M44.00M11.60M300.00K-7.40M6.40M
Net Income Margin11.50%5.99%2.73%9.62%2.43%0.06%-1.53%1.43%
R&D22.50M22.90M20.20M23.00M23.60M25.70M25.40M19.60M
R&D as % of Total Revenue4.96%5.44%5.75%5.03%4.95%5.28%5.25%4.38%
Interest Expense7.30M7.30M7.80M8.40M6.50M10.10M11.80M9.00M
Interest Expense % of Total Revenue1.61%1.74%2.22%1.84%1.36%2.08%2.44%2.01%

Balance Sheet

Currency: CHF2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets718.10M697.00M789.90M974.40M1.11B1.01B954.20M969.30M
Total Liabilities378.40M401.90M456.50M440.50M601.10M532.40M507.50M536.50M
Total Equity339.70M295.10M333.40M533.90M504.80M465.40M436.40M425.70M
Cash16.20M4.50M14.80M209.80M313.50M130.60M96.20M105.50M
Total Debt260.10M276.60M332.30M320.90M473.50M349.70M323.40M330.30M
Net Debt243.90M272.10M317.50M111.10M160.00M219.10M227.20M224.80M

Cash Flow

Currency: CHF2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow94.20M89.10M50.60M87.30M47.60M56.10M86.60M67.80M
Investing Cash Flow-33.20M-39.60M4.40M-3.30M-57.00M-80.60M-51.50M-40.70M
Financing Cash Flow-46.40M-59.00M-42.90M111.60M116.10M-153.80M-48.60M-36.30M
Capital Expenditure30.00M36.20M43.10M31.90M38.60M52.90M48.50M34.50M
Free Cash Flow64.20M52.90M7.50M55.40M9.00M3.20M38.10M33.30M
Dividends Paid47.20M55.00M52.00M41.30M15.00M15.00M15.00M15.00M
FCF to OCF68.15%59.37%14.82%63.46%18.91%5.70%44.00%49.12%
Dividend Paid to FCF73.52%103.97%693.33%74.55%166.67%468.75%39.37%45.05%

Earnings

Report DateAug 20, 2021Feb 21, 2022Aug 4, 2022Feb 22, 2023Feb 25, 2025Jul 22, 2025Feb 25, 2027
EPS Estimate0.000.000.000.000.000.00-
EPS Actual0.120.440.58-0.30-0.330.16-
Surprise-------
TimingPre-marketAfter-hoursPre-market---Pre-market

Key Statistics & Ratios

Market Cap412.47M
Enterprise Value620.16M
Trailing P/E0.00
Forward P/E9.58
Price / Sales0.94
Price / Book0.97
EPS0.00
Book Value10.44
Revenue (TTM)437.00M
Gross Profit (TTM)160.50M
EBITDA71.60M
Profit Margin0.02%
Operating Margin7.74%
Return on Equity0.21%
Return on Assets1.88%
Shares Outstanding41.71M
Shares Float39.34M
Beta0.83
Dividend Yield1.01%
Dividend Rate0.10
Payout Ratio333.33%

Dividends

20261×
0.10Apr 20, 2026
20251×
0.50Apr 25, 2025
20241×
0.50Apr 26, 2024
20231×
0.50May 3, 2023
20221×
0.50Apr 14, 2022